ATE507215T1 - Verbesserte synthese und zubereitungen von duloxetinsalzen - Google Patents

Verbesserte synthese und zubereitungen von duloxetinsalzen

Info

Publication number
ATE507215T1
ATE507215T1 AT06850470T AT06850470T ATE507215T1 AT E507215 T1 ATE507215 T1 AT E507215T1 AT 06850470 T AT06850470 T AT 06850470T AT 06850470 T AT06850470 T AT 06850470T AT E507215 T1 ATE507215 T1 AT E507215T1
Authority
AT
Austria
Prior art keywords
preparations
improved synthesis
duloxetine
salts
duloxetine salts
Prior art date
Application number
AT06850470T
Other languages
English (en)
Inventor
Stephen Winter
Original Assignee
Medichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38437735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE507215(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medichem Sa filed Critical Medichem Sa
Application granted granted Critical
Publication of ATE507215T1 publication Critical patent/ATE507215T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06850470T 2005-12-12 2006-12-12 Verbesserte synthese und zubereitungen von duloxetinsalzen ATE507215T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US74909505P 2005-12-12 2005-12-12
US74909705P 2005-12-12 2005-12-12
US74909605P 2005-12-12 2005-12-12
US81585606P 2006-06-23 2006-06-23
US81585406P 2006-06-23 2006-06-23
US81583506P 2006-06-23 2006-06-23
PCT/IB2006/004250 WO2007119114A2 (en) 2005-12-12 2006-12-12 Improved synthesis and preparations of duloxetine salts

Publications (1)

Publication Number Publication Date
ATE507215T1 true ATE507215T1 (de) 2011-05-15

Family

ID=38437735

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06850470T ATE507215T1 (de) 2005-12-12 2006-12-12 Verbesserte synthese und zubereitungen von duloxetinsalzen

Country Status (9)

Country Link
US (4) US20090182156A1 (de)
EP (3) EP1971593A2 (de)
AR (1) AR058321A1 (de)
AT (1) ATE507215T1 (de)
CA (3) CA2634007A1 (de)
DE (1) DE602006021628D1 (de)
IL (3) IL192115A0 (de)
PL (1) PL1971592T3 (de)
WO (3) WO2007119114A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096809A1 (en) 2005-03-08 2006-09-14 Teva Pharmaceutical Industries Ltd. Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
US7534900B2 (en) 2005-03-14 2009-05-19 Teva Pharmaceutical Industries Ltd Process for the purification of duloxetine hydrochloride
EP1838692A2 (de) 2005-09-22 2007-10-03 Teva Pharmaceutical Industries Ltd Dnt-maleat und herstellungsverfahren dafür
WO2007067581A1 (en) 2005-12-05 2007-06-14 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphthol) thiophene, an impurity of duloxetine hydrochloride
DE602006021628D1 (de) 2005-12-12 2011-06-09 Medichem Sa Verbesserte synthese und zubereitungen von duloxetinsalzen
EP1888554A2 (de) 2006-02-21 2008-02-20 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung von (s)-(-)-n,n-dimethyl-3-(2-thienyl)-3-hydroxypropanamin, einem duloxetin-zwischenprodukt
HU228458B1 (en) 2006-03-13 2013-03-28 Egis Gyogyszergyar Nyrt Duloxetine salts for producing pharmaceutical compositions
WO2007134168A2 (en) * 2006-05-10 2007-11-22 Dr. Reddy's Laboratories Ltd. Process for preparing duloxetine
WO2009019719A2 (en) * 2007-08-09 2009-02-12 Ind-Swift Laboratories Limited Process for the preparation of 3-aryloxy-3-arylpropanamines
EP2107057A1 (de) 2008-04-04 2009-10-07 Ranbaxy Laboratories Limited Verfahren zur Herstellung von reinem Duloxetin
WO2011092065A1 (en) * 2010-01-29 2011-08-04 Nicox S.A. Nitric oxide releasing compounds for the treatment of neurophatic pain
CN103896910B (zh) * 2012-12-27 2016-02-03 成都国弘医药有限公司 一种度洛西汀的合成方法
CN103524480B (zh) * 2013-10-21 2016-04-20 山东鲁药制药有限公司 一种盐酸度洛西汀的制备方法
CN104478849A (zh) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 制备去甲肾上腺素再摄取双重抑制剂的方法
JP2016172704A (ja) * 2015-03-17 2016-09-29 株式会社トクヤマ デュロキセチン塩酸塩の製造方法、及び新規な結晶構造のデュロキセチン塩酸塩
CN107382958B (zh) * 2017-07-05 2021-11-09 浙江华海药业股份有限公司 一种度洛西汀中间体的结晶方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
HU9202128D0 (en) 1992-06-26 1992-10-28 Richter Gedeon Vegyeszet Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
AU3877500A (en) 1999-04-09 2000-11-14 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
US20040053948A1 (en) * 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
JP2006508909A (ja) * 2002-08-06 2006-03-16 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの新規な結晶形
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
WO2006027798A2 (en) 2004-08-05 2006-03-16 Sun Pharmaceutical Industries Limited A process for preparation of an antidepressant compound
CZ297560B6 (cs) 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
JP2007523213A (ja) 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
US7534900B2 (en) 2005-03-14 2009-05-19 Teva Pharmaceutical Industries Ltd Process for the purification of duloxetine hydrochloride
EP1838692A2 (de) 2005-09-22 2007-10-03 Teva Pharmaceutical Industries Ltd Dnt-maleat und herstellungsverfahren dafür
DE602006021628D1 (de) 2005-12-12 2011-06-09 Medichem Sa Verbesserte synthese und zubereitungen von duloxetinsalzen
CZ299270B6 (cs) * 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu

Also Published As

Publication number Publication date
US20090093645A1 (en) 2009-04-09
WO2007119116A2 (en) 2007-10-25
CA2634008A1 (en) 2007-10-25
IL192116A0 (en) 2009-08-03
US8158808B2 (en) 2012-04-17
WO2007096707A3 (en) 2008-01-24
WO2007119116A3 (en) 2008-01-31
US20100286412A1 (en) 2010-11-11
IL192114A0 (en) 2009-08-03
WO2007119114A2 (en) 2007-10-25
EP1971592B1 (de) 2011-04-27
AR058321A1 (es) 2008-01-30
IL192115A0 (en) 2009-08-03
EP1971593A2 (de) 2008-09-24
WO2007096707A2 (en) 2007-08-30
CA2634009A1 (en) 2007-10-25
EP1971591A2 (de) 2008-09-24
DE602006021628D1 (de) 2011-06-09
US20090221668A1 (en) 2009-09-03
US20090182156A1 (en) 2009-07-16
PL1971592T3 (pl) 2011-09-30
WO2007119114A3 (en) 2008-01-24
CA2634007A1 (en) 2007-08-30
EP1971592A2 (de) 2008-09-24

Similar Documents

Publication Publication Date Title
ATE507215T1 (de) Verbesserte synthese und zubereitungen von duloxetinsalzen
DE602006012450D1 (de) Exo- und diastereoselektive synthese von himbacin-analoga
CY2017048I2 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
ATE359787T1 (de) Kontrollierte synthese von ziprasidon
ATE365169T1 (de) Regioselektive synthese von cci-779
ATE486853T1 (de) Synthese von acylaminoalkenylenamiden als substanz-p-antagonisten
ATE472527T1 (de) Synthese und verwendungen von 2-oxo-4- methylthiobuttersäure, deren salze und deren derivate
FR2886845B1 (fr) Produit cosmetique solide
DE602006004463D1 (de) Kristallform von asenapinmaleat
ATE500249T1 (de) Synthese von himbacinanaloga
DE602005005941D1 (de) Monohydrochloridsalz von 1-Ä3-Ä3-(4-Chlorophenyl)propoxyÜpropylÜ-piperidin
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
DE602006018590D1 (de) Heteroarylharnstoffderivate zur hemmung von chk1
ATE405326T1 (de) Kosmetiktuchprodukt
DE602005020603D1 (de) Synthese von trithiocarbonat-raft-agentia und zwischenprodukte daraus
DE602005005645D1 (de) Stereoselektive synthese von vitamin-d-analoga
DE602005025521D1 (de) Synthese von aminosäure-n-carboxyanhydriden
DE602006013028D1 (de) Lösungsphasensynthese von leuprolid und dessen zwischenprodukten
ATE443512T1 (de) Pharmazeutische zusammensetzung von piperazinderivaten
ATE459627T1 (de) Synthesen und herstellungen von narwedin und verwandten neuen verbindungen
ATE497504T1 (de) Aminoderivate von b-homoandrostanen und b- heteroandrostanen
DE602006006853D1 (de) Synthese von neuem Dihydrobenzoxazin
ATE402145T1 (de) Synthese von pyrrol-2-carbonsäurenitrilen
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
FI20050453A0 (fi) Ihonhoitokoostumus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties